This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.
Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.
Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.
Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.
A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.
The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)
Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.
The blood-brain barrier (BBB) in glioblastoma patients was opened temporarily using a novel, skull-implantable ultrasound device to deliver chemotherapy to the brain in a first in-human trial. Two chemotherapy drugs , paclitaxel and carboplatin were injected intravenously during the four-minute procedure.
Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.
The use of atorvastatin prior to anthracycline-based chemotherapy in lymphoma patients reduces the subsequent development of cardiac dysfunction, according to the findings of a randomised trial. The post Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy appeared first on Hospital Pharmacy Europe.
This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.
A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. The post Non-chemotherapy lymphoma treatment may provide durable remission appeared first on European Pharmaceutical Review.
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.
A significant and increasing trend towards the use of a three-month rather than six-month adjuvant chemotherapy regime in stage 3 colon cancer has been observed following publications from the IDEA collaboration abstract. In addition, CAPOX prescribing also significantly increased from 14% to 48% (p <0.001).
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.
A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.
Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.
In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.
Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.
The indication is for adult patients with primary advanced or recurrent endometrial carcinoma and is the third indication that pembrolizumab has received for this disease state.
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR).
Survivorship care for patients with colon cancer should include comprehensive coordination between oncologists, specialists, and primary care providers and include psychological and economic factors in addition to standard health recommendations.
High-dose vitamin C, when combined with chemotherapy, has shown the potential to double the survival rate of patients with late-stage metastatic pancreatic cancer.
The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal. In the study, adding retifanlimab to chemotherapy cut the risk of disease progression or death by more than a third.
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The standard treatment after surgery for these patients is chemotherapy.
Nivolumab is the only PD-1 inhibitor to show statistically significant and clinically meaningful benefits in non-small cell lung cancer compared with chemotherapy.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content